Presiding over the upward trajectory of Eli Lilly over the last eight years is paying off nicely for CEO David Ricks. | ...

The FDA has granted a speedy review of Eli Lilly and Boehringer Ingelheim’s Jardiance for a potential new use, to reduce the risk of renal failure and cardiovascular death in people with chronic ...

Additionally, Eli Lilly’s older diabetes drug, Jardiance, saw better-than-expected sales, contributing $1.20 billion in revenue, a 50% increase from the prior year. This includes a one-time ...

Whales with a lot of money to spend have taken a noticeably bullish stance on Eli Lilly. Looking at options history for Eli ...

There are hints that the 10-year benefit seen in STICHES, the earlier trial, might be the result of inferior medical therapy.

Eli Lilly and Company ( NYSE:LLY – Get Free Report) last announced its quarterly earnings data on Thursday, February 6th. The ...

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include ...

Diabetes medications Jardiance and Humalog saw sales jump ... the autoimmune drug Taltz saw revenue rise 21% to $952 million. Source: Eli Lilly.

Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology. Where Is Eli Lilly ...

30-Day Overview Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance ...

Eli Lilly continues to see strong growth coming ... Diabetes medications Jardiance and Humalog saw sales jump 50% and 69% to $1.2 billion and $620 million, respectively. Meanwhile, the autoimmune ...